| 王涛.舒利迭联合噻托溴铵粉吸入剂对哮喘患者疗效及炎症因子、免疫功能的影响[J].浙江中西医结合杂志,2021,31(2): |
| 舒利迭联合噻托溴铵粉吸入剂对哮喘患者疗效及炎症因子、免疫功能的影响 |
| Effects of sullidione combined with tiotropium bromide on the efficacy, inflammatory factors and immune function of asthmatic patients |
| 投稿时间：2020-04-02 修订日期：2021-01-20 |
| DOI： |
| 中文关键词: 舒利迭 塞托溴铵粉吸入剂 哮喘 炎症因子 免疫功能 |
| 英文关键词:Seretide Setoprobromide powder inhalation Asthma Inflammatory factors Immune function |
| 基金项目: |
|
| 摘要点击次数: 560 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的：探讨舒利迭联合塞托溴铵粉吸入剂对哮喘患者疗效及炎症因子以及免疫功能的影响。方法：选取我院2017年10月-2018年11月明确诊断为支气管急性发作期(中度)的患者60例,按照随机数字表法分为观察组(在常规治疗的基础上给予舒利迭联合塞托溴铵粉吸入剂,连续治疗7d)和对照组(在常规治疗的基础上联合舒利迭, 连续治疗7d)各30例。比较治疗3个疗程后两组患者的疗效,并对比治疗前及治疗3个疗程后的单个证候积分指标、血清IL-4、IL-17、细胞免疫功能指标(CD3+、CD4+、CD8+及CD4+/ CD8+)、体液免疫功能指标(IgA、IgG、IgM)的水平。结果：治疗前,两组单个症状比较,差异不显著(P＞0.05)；治疗后,两组单个症状均较治疗前改善明显,且观察组优于对照组,差异显著(P＜0.05)。治疗前,两组患者FEVl、FEVl／FVc、MMEF、PEF指标水平比较,差异不显著(P>0.05)；治疗后,两组FEVl、FEVl／FVc、MMEF、PEF指标水平均明显高于治疗前,差异显著(P<0.05)；且观察组FEVl、FEVl／FVc、MMEF、PEF指标水平明显高于对照组,差异显著(P<0.05。对照组总有效率为80%,观察组总有效率为86.7,相比之下,观察组效果优于对照组,差异显著(P＜0.05)。治疗前,两组IL-4、IL-17比较,差异不显著(P>0.05)；治疗后,两组IL-4、IL-17均降低,其中观察组IL-4、IL-17明显低于对照组,差异显著(P＜0.05)。治疗前,两组患者细胞免疫功能指标水平比较,差异不显著(P>0.05)；治疗4d后及7d后,两组CD3+、CD4+及CD4+/ CD8+水平明显高于治疗前,而CD8+水平明显低于治疗前,差异显著(P<0.05)；且观察组CD3+、CD4+及CD4+/ CD8+水平明显高于对照组,CD8+水平明显低于对照组,差异显著(P<0.05)。治疗前,两组的IgA、IgG、IgM水平比较,差异不显著(P>0.05)；治疗4d后及7d后,两组的上述指标水平较治疗前均明显降低,差异显著(P<0.05),观察组的上述指标水平明显高于对照组,差异显著(P<0.05)。结论：舒利迭联合塞托溴铵粉吸入剂可以有效控制哮喘患者症状体征,提高临床疗效,降低炎症反应,改善患者的细胞免疫、体液免疫。 |
| 英文摘要: |
| Objective:To investigate the effect of sullidene combined with cetoammonium bromide on the efficacy, inflammatory factors and immune function of asthmatic patients. Methods:Selected from October 2017 - November 2018 clear diagnosis of bronchial 60 patients with acute period (moderate), according to random number table method divided into observation group (on the basis of routine therapy for nimesulide lap joint plug bromide powder inhaler, continuous treatment of 7d) and the control group (on the basis of conventional treatment combined nimesulide idea, continuous treatment of 7d) 30 cases each. The efficacy of the two groups after 3 courses of treatment was compared, and the levels of single syndrome score index, serum il-4, il-17, cellular immune function index (CD3+, CD4+, CD8+ and CD4+/ CD8+) and humoral immune function index (IgA, IgG, IgM) before and after 3 courses of treatment were compared.Results: Before treatment, there was no significant difference in single symptom between the two groups (P > 0.05). After treatment, individual symptoms in both groups improved significantly compared with those before treatment, and the observation group was superior to the control group, with significant differences (P < 0.05). Before treatment, there was no significant difference in the levels of FEVl, FEVl/FVc, MMEF and PEF in the two groups (P>0.05). After treatment, the levels of FEVl, FEVl/FVc, MMEF and PEF in the two groups were significantly higher than before treatment, with significant differences (P<0.05). The levels of FEVl, FEVl/FVc, MMEF and PEF in the observation group were significantly higher than those in the control group, with significant differences (P<0.05). The total effective rate of the control group was 80%, and that of the observation group was 86.7. In comparison, the effect of the observation group was better than that of the control group, and the difference was significant (P < 0.05). Before treatment, there was no significant difference in il-4 and il-17 between the two groups (P>0.05). After treatment, il-4 and il-17 were decreased in both groups, of which il-4 and il-17 in the observation group were significantly lower than those in the control group, with a significant difference (P < 0.05). Before treatment, there was no significant difference in the level of cellular immune function between the two groups (P>0.05). After 4d and 7d of treatment, the levels of CD3+, CD4+ and CD4+/ CD8+ in the two groups were significantly higher than before treatment, while the levels of CD8+ were significantly lower than before treatment, with significant differences (P<0.05). Moreover, the levels of CD3+, CD4+ and CD4+/ CD8+ in the observation group were significantly higher than those in the control group, and the levels of CD8+ were significantly lower than those in the control group, with significant differences (P<0.05). Before treatment, the IgA, IgG and IgM levels of the two groups were not significantly different (P>0.05). After 4d and 7d of treatment, the level of the above indicators in the two groups was significantly lower than that before treatment, with significant difference (P<0.05). The level of the above indicators in the observation group was significantly higher than that in the control group, with significant difference (P<0.05).Conclusion: Seretide combined with cetoprazolium bromide powder inhalation can effectively control the symptoms and signs of asthma patients, improve clinical efficacy, reduce inflammation and improve cellular and humoral immunity. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
